Mesothelioma Progression-Free Survival Does Not Improve With Anetumab Ravtansine
Median overall survival increased from 10.1 months with anetumab ravtansine to 11.6 months with vinorelbine.
All articles by Jonathan Goodman
Dacomitinib vs Gefitinib for Progression-Free Survival in Non-small Cell Lung Cancer
Dacomitinib improved progression-free survival in patients with non-small cell lung cancer.
Non-small Cell Lung Cancer Metastasis at Diagnosis May Be Predicted by Genetic Mutations
ROS1 and ALK rearrangements in patients with non-small cell lung cancer may predict different metastasis distributions at diagnosis.
Predicting Overall Survival With Neutrophil-Lymphocyte Ratio in NSCLC
Valuable information regarding patients’ life expectancy can be collected through neutrophil-lymphocyte ratio biomarkers.
Efficacy of Once- vs Twice-daily Ratiotherapy for SCLC With Concurrent Chemoradiotherapy
The randomzied, phase 3 CONVERT trial examined 547 patients with small-cell lung cancer.
Treating Limited-stage Small-cell Lung Cancer With Proton-beam Tx
Results showed that proton-beam therapy in small-cell lung cancer can be safe in combined modality therapy.
NSCLC: Timing in EGFR mutation-related ctDNA Test Results
Timing might affect the results of an EGFR mutation-frequency circulating tumor DNA test among patients with advanced non-small cell lung cancer.
FDA Approval: Osimertinib indication for EGFR T790M Mutation-positive NSCLC
The FDA approved osimertinib for treatment of EGFR T790M mutation positive non-small cell lung cancer.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...